Juno Therapeutics, Inc. a Bristol Myer-Squibb Company
BiotechJuno Therapeutics, Inc. a Bristol Myer-Squibb Company is a biotechnology company focused on Immunology, Dermatology. Key products include Breyanzi.
Upcoming FDA Decisions
Full Calendar →Juno Therapeutics, Inc. a Bristol Myer-Squibb Company's Key Drugs
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company's core commercial portfolio centers on Breyanzi, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company's Recent FDA Approvals
New NDA/BLA approvals for Juno Therapeutics, Inc. a Bristol Myer-Squibb Company over the last two years — novel drugs only, excluding generics and label supplements.
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company's Therapeutic Areas
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company's Top Competitors
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company Pipeline Snapshot
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company has 15 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Breyanzi leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2021-02-04
- Latest
- 2021-02-04
- Applications
- 1